{
    "2019-08-13": [
        [
            {
                "time": "2019-08-15",
                "original_text": "长春高新营销费用增两成，研发仅增3.79%",
                "features": {
                    "keywords": [
                        "营销费用",
                        "研发",
                        "增长"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-08-15",
                "original_text": "受疫苗业务拖累，长春高新第二季度营收同比下降5.89%，盈利能力下降",
                "features": {
                    "keywords": [
                        "疫苗业务",
                        "拖累",
                        "营收下降",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-08-15",
                "original_text": "长春高新（000661）：业绩基本符合预期，金赛药业延续高增长态势【中报点评|西南医药朱国广陈铁林团队】",
                "features": {
                    "keywords": [
                        "金赛药业",
                        "高增长",
                        "中报点评"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-08-15",
                "original_text": "长春高新（000661）2019年中报点评：疫苗行业冲击，金赛气势如虹",
                "features": {
                    "keywords": [
                        "疫苗行业冲击",
                        "金赛",
                        "高增长"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-15",
                "original_text": "长春高新2019年中报点评:生长激素高增长符合预期,疫苗业务下半年有望大幅好转",
                "features": {
                    "keywords": [
                        "生长激素",
                        "高增长",
                        "疫苗业务",
                        "下半年好转"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-15",
                "original_text": "长春高新:半年报增长稳健,第二季度增速有所放缓",
                "features": {
                    "keywords": [
                        "半年报",
                        "增长稳健",
                        "第二季度增速放缓"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-08-15",
                "original_text": "医药生物行业跨市场周报:关注中报业绩与政策边际改善,紧握优质公司",
                "features": {
                    "keywords": [
                        "医药生物",
                        "中报业绩",
                        "政策边际改善",
                        "优质公司"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}